Searchable abstracts of presentations at key conferences on calcified tissues

ba0001oc1.6 | Osteoporosis epidemiology and long term treatment complications | ECTS2013

Femur geometrical parameters in the pathogenesis of atypical femur fractures

Morin Suzanne N , Godbout Benoit , Wall Michelle , Belzile Etienne L , Michou Laetitia , Ste-Marie Louis-Georges , Karaplis Andrew C , de Guise Jacques A , Brown Jacques P

Background: Atypical femur fractures (AFF) arise in the subtrochanteric and diaphyseal regions. Because of this unique distribution, we hypothesized that patients with AFF demonstrate specific geometrical variations of their femur whereby baseline tensile forces applied to the lateral cortex are higher and might favor the appearance of these rare stress fractures, when exposed to bisphosphonates.Methods: Subjects who sustained AFF, as defined by the ASBM...

ba0001pp128 | Calciotropic and phosphotropic hormones and mineral metabolism | ECTS2013

Mass spectrometric immunoassay for intact parathyroid hormone: correlation with immunoassay and application to clinical samples

Couchman L , Taylor D , Krystans B , Lopez M , Prakash A , Sarracino D , Garces A , Vogelsang M , Peterman S , Vadali G , Robinson S , Moniz C

Introduction: Parathyroid hormone (PTH) measurement is of use in i) differential diagnosis of hypercalcaemia and ii) patients with renal impairment at risk of bone disease. PTH immunoassays are complicated by cross-reactivity with truncated (inactive) variant forms, which accumulate in patients with renal impairment. PTH assay variability is a critical governance issue in renal medicine, suggesting an MS-based reference method is required.Aim: To develop...

ba0001pp450 | Osteoporosis: treatment | ECTS2013

Transdermal delivery of BA058, a novel analog of hPTHrP (1-34), with a short wear time patch in preclinical and clinical studies

Hattersley Gary , Hansen Kris , Determan Amy , Brown Ken , Mckay Kate , Guerriero Jonathan , McCarthy Dan , Lyttle C Richard , St L O'Dea Louis

BA058 is being developed as an anabolic therapy for the treatment of osteoporosis. Daily BA058 SC injection has produced promising safety and efficacy results in early clinical studies, and is currently enrolling in a Phase 3 fracture prevention study. There is, however, a significant need for an alternative to injection that improves patient convenience and compliance. We have investigated the use of a solid Microstructured Transdermal System (3M) for transdermal (TD) deliver...

ba0002p70 | (1) | ICCBH2013

Isolated bilateral zeugo-autopodal segments agenesis of the lower limb: unusual malformation case report

Christiaens Antoine , Deprez Pierre M L , Mendola Antonella , Bernard Pierre , Gillerot Yves , Clapuyt Philippe , Lengele Benoit G , Vikkula Miikka , Nyssen-Behets Catherine

: Congenital limb abnormalities represent a prevalence of 0.79/1000 of live births in Massachusetts1. A better understanding of their physiopathology could improve the management of the patients. We report on a 23 weeks female fetus affected by an isolated bilateral terminal transverse defect of the lower limbs with nubbins. Both familial history and chromosomal analyses were irrelevant. We performed a deep morphological examination of the fetus in comparison with a...

ba0002p185 | (1) | ICCBH2013

An unusual presentation of progressive osseous heteroplasia in a 7-year-old female child

Schrander D E , Welting T J , Schrander J J P , van Rhijn L W , Korver-Keularts I , Schrander-Stumpel C T R M

Background: Progressive osseous heteroplasia (POH) (OMIM 166350) is a rare autosomal dominant condition, characterized by heterotopic ossification of the skin, subcutaneous fat and deep connective tissue. This condition is distinct from Albright’s hereditary osteodystrophy or Mccune–Albright syndrome (AHO) (OMIM 103580) and fibrodysplasia ossificans progressiva (FOP) (OMIM 135100).Presenting problem: We present an unu...

ba0003pp187 | Genetics | ECTS2014

A novel mutation in IFITM5, encoding BRIL, impairs osteoblast production of PEDF and causes atypical type VI osteogenesis imperfecta

Reich Adi , Farber Charles R , Barnes Aileen M , Becerra Patricia , Rauch Frank , Cabral Wayne A , Bae Alison , Glorieux Francis H , Clemens Thomas L , Marini Joan C

Osteogenesis imperfecta (OI) type V is caused by a unique dominant mutation (c.−14C>T) in IFITM5, which encodes BRIL, a transmembrane ifitm-like protein most strongly expressed in osteoblasts, while type VI OI is caused by recessive null mutations in SERPINF1, encoding pigment epithelium-derived factor (PEDF). We identified a 25-year-old woman with severe OI, whose dermal fibroblasts and cultured osteoblasts displayed minimal secretion of PEDF, but ...

ba0003pp205 | Muscle, physical activity and bone | ECTS2014

Volumetric bone mineral density at the distal radius in premenopausal Spanish women and grip strength: role of calcium intake

Moran Jose , Maria L Canal-Macias , Roncero Raul , Lavado-Garcia Jesus M , Calderon-Garcia Julian F , Rey-Sanchez Purificacion , Pedrera-Zamorano Juan D

Peripheral computed tomography (pQCT) can estimate volumetric bone mineral density (vBMD) and distinguish trabecular from cortical bone. Few comprehensive studies have examined correlates of vBMD in Spanish premenopausal women.The aim was to study the association between bone microarchitecture, muscle mass and strength in premenopausal Spanish women and to evaluate the role of calcium intake. vBMD was assessed in 164 premenopausal women at the distal rad...

ba0003pp331 | Osteoporosis: treatment | ECTS2014

Prevalence of osteoporosis treatment depending on the risk evaluation of the osteoporotic fractures in patients with rheumatoid arthritis in Russia

Dydykina Irina , Vetkova Elizaveta , Podvorotova Marina , Taskina E , Smirnov A , Sinenko A , Ruskina T , Peshekhonov D , Myasoedova S , Zavodovski B , Dydykina P , Petrova E , Zhigulin V , Alekseeva L , Nasonov E

Background: It is known that one of the features of rheumatoid arthritis (RA) is a generalized bone loss, therefore important tasks for the physician are timely evaluating of the risk of fractures and approving osteoporosis treatment in patients with RA.Objectives: Through the Programme of the Russian Association of Rheumatology for the diagnosis, prevention and treatment osteoporosis (OP) in patients with RA we evaluated the 10 year probability of major...

ba0003pp354 | Osteoporosis: treatment | ECTS2014

Denosumab treatment in women with osteoporosis reduces hip cortical porosity

Zebaze Roger M , Libanati Cesar , McClung Michael R , Zanchetta Jose R , Kendler David L , Hoiseth Arne , Wang Andrea , Ghasem-Zadeh Ali , Seeman Ego

Bone strength is influenced by cortical thickness, area, mass and porosity, all of which contribute to nonvertebral fracture risk. Cortical porosity is one parameter of structural decay associated with bone fragility. This is caused by unbalanced and accelerated remodelling of Haversian units which enlarge, coalesce and fragment the cortex. Antiresorptive therapies will limit progression of cortical porosity; reducing existing porosity would be a goal for those already at incr...